Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-02-28
2006-02-28
Kemmerer, Elizabeth (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200, C530S399000, C530S351000, C530S387100
Reexamination Certificate
active
07005413
ABSTRACT:
The present invention discloses a novel secreted polypeptide, termed osteoprotegerin, which is a member of the tumor necrosis factor receptor superfamily and is involved in the regulation of bone metabolism. Also disclosed are nucleic acids encoding osteoprotegerin, polypeptides, recombinant vectors and host cells for expression, antibodies which bind OPG, and pharmaceutical compositions. The polypeptides are used to treat bone diseases characterized by increased resorption such as osteoporosis. Methods of treatment are described using the polypeptides in conjunction with various agents, including IL-1 inhibitors, TNF-α inhibitors, and serine protease inhibitors.
REFERENCES:
patent: 6288032 (2001-09-01), Boyle et al.
patent: 0 784 093 (1997-07-01), None
patent: WO 93/21946 (1993-11-01), None
patent: WO 98/01555 (1998-01-01), None
Miyagum K. Cytokines in patients with multiple sclerosis. Abstract Shinshu Igaku Zasshi 40 (6), 567-75 (1992).
Murray et al. Abstract Recombinant human tumor necrosis factor receptor (p75) Fc fusion protein (TNFR:Fc) in rheumatoid arthritis. Ann Pharmacother Nov. 1997; 31 (11):1335-8.
Nieves et al. High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology 44 (9) 1687-92 Sep. 1994.
Martin et al. (1998), “Interleukins in the Control of Osteoclast Differentiation,”Critical Reviews™ in Eukaryotic Gene Expression8(2):107-123.
Roodman (1993), “Role of Cytokines in the Regulation of Bone Resorption,”Calcif Tissue Int. 53(S1):S94-S98.
Boyle William J.
Calzone Frank J.
Chang Ming-Shi
Lacey David Lee
Amgen Inc.
DeBerry Regina M.
Gaw Timothy J.
Kemmerer Elizabeth
Levy Ron K.
LandOfFree
Combination therapy for conditions leading to bone loss does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination therapy for conditions leading to bone loss, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination therapy for conditions leading to bone loss will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3665669